OTC Medicines

In recent years, the issue of consumer data privacy has become increasingly important as technology continues to advance, and more personal information is collected and shared online. Despite the growing concerns over data privacy, the federal government has yet to enact comprehensive legislation addressing the issue. This lack of federal action has prompted many states to take matters into their own hands and introduce their own data privacy laws to protect their residents.

(WASHINGTON, D.C.) – Representatives from the Consumer Healthcare Products Association (CHPA), Sanofi Consumer Healthcare, Haleon, Kenvue, and Bayer participated in a discussion this week hosted by U.S. Rep. Bob Latta (OH-05) to provide an analysis of the over-the-counter (OTC) Monograph Drug User Fee Program (OMUFA), how some OTCs come to market through the Rx-to-OTC-switch process, how these products are regulated by the U.S. Food and Drug Administration (FDA), and industry’s efforts to expand HSA/FSA coverage for dietary supplements and oral care products.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following the adoption of Kentucky House Bill 386 into law, legislation that will eliminate the state’s annual purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE), which is currently the most restrictive yearly limit nationwide at 24 grams, or roughly a three-month supply.

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today following West Virginia Governor Jim Justice signing Senate Bill (SB) 688 into law. This legislation lifts the annual purchasing limits for common over-the-counter cold and allergy

“Consumers can be confident that over-the-counter (OTC) acne products containing benzoyl peroxide (BPO) are stable and safe under the specified storage conditions on their labels.

Washington, D.C. – The annual Monitoring the Future survey (MTF), conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA), shows that the percentage of adolescents reporting any substance use in 2023 continues to “hold steady” and remains below pre-pandemic levels, including abuse of over-the-counter (OTC) cough & cold medicines.